Alaunos Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the fiscal quarter ended September 30, 2026, disclosing a sharp decline in cash and total assets alongside ongoing going-concern risks.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $615 thousand as of September 30, 2026, down from $1,385 thousand at December 31, 2025, according to the filing.
  • Total assets: Total assets were $1,918 thousand at September 30, 2026, compared to $2,966 thousand at December 31, 2025, the company disclosed.
  • Total liabilities: Total liabilities were $947 thousand at September 30, 2026, up from $813 thousand at December 31, 2025, per the filing.
  • Shares outstanding: As of November 16, 2026, the company reported 4,208,359 shares of common stock outstanding at a par value of $0.001 per share.
  • Going-concern disclosure: The filing lists among its forward-looking statements "our ability to raise substantial additional capital to continue as a going concern and fund our planned operations."
  • Nasdaq compliance risk: The company disclosed uncertainty around remaining listed on the Nasdaq Capital Market, citing compliance requirements including a minimum stockholders' equity of $2.5 million and a minimum bid price of $1.00.
  • Program focus: The company described ongoing preclinical work on its Obesity and Metabolic Disorders Program, including a candidate referred to as ALN1003, with efforts directed toward IND-enabling activities.

Alaunos Reports Declining Cash and Assets in September 2026 Quarter

Alaunos Therapeutics, Inc. (NASDAQ:TCRT), a Delaware-incorporated biotechnology company headquartered at 501 E. Las Olas Blvd., Suite 300, Fort Lauderdale, FL 33301, filed its quarterly report covering the period ended September 30, 2026. The filing shows cash and cash equivalents of $615 thousand at the close of the quarter, a decline from $1,385 thousand reported at December 31, 2025. Total assets fell to $1,918 thousand from $2,966 thousand over the same period, according to the condensed balance sheets included in the report.

On the liabilities side, accounts payable rose to $796 thousand from $613 thousand, and accrued expenses decreased to $151 thousand from $200 thousand, bringing total current liabilities to $947 thousand as of September 30, 2026, compared to $813 thousand at year-end 2025. The filing identifies Series A-1 preferred stock with 1,000 shares authorized and 500 shares issued and outstanding at both reporting dates, carrying a par value of $0.001 per share.

The company disclosed that its forward-looking statements, which are subject to its cautionary language under the Private Securities Litigation Reform Act of 1995, include statements regarding its ability to raise additional capital to continue as a going concern, to advance ALN1003 through IND-enabling activities, and to pursue partnerships or licensing arrangements for its Obesity and Metabolic Disorders Program. The filing also notes the company's efforts to monetize legacy TCR-T intellectual property and to maintain compliance with Nasdaq Capital Market continued listing standards.

What Was Disclosed

Alaunos Therapeutics filed a 10-Q for the quarter ended September 30, 2026, reporting cash of $615 thousand, total assets of $1,918 thousand, total liabilities of $947 thousand, and 4,208,359 shares outstanding, alongside disclosures about going-concern risk and Nasdaq listing compliance.